Therapeutic Choices in dMMR Recurrent or Advanced Endometrial Cancer
This roundtable series reviews options after progression on platinum-regimens for patients with mismatch repair–deficient recurrent or advanced endometrial cancer, as discussed by key opinion leaders and participants at virtual live events.
Selecting Therapy for dMMR/MSI-H Endometrial Cancer After Chemotherapy
August 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed the treatment options for a patient with endometrial cancer who relapsed following resection and again following a complete response to chemotherapy. This is the first of 2 articles based on this event.
Physicians Discuss Immunotherapy Discontinuation in Endometrial Cancer
September 6th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed trials of immune checkpoint inhibition and when to discontinue treatment in patients with endometrial cancer. This is the second of 2 articles based on this event.
Considerations for Ordering Biomarker Testing in Endometrial Cancer
October 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the importance of mismatch repair deficiency testing and the value of next-generation sequencing in patients with advanced endometrial cancer.
Factors Influencing Treatment Post-Chemo in dMMR Endometrial Cancer
November 9th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the use of immune checkpoint inhibitors in patients with advanced endometrial cancer. This is the second of 2 articles based on this event.
